Physician profile
Albert D Kramer
NPI 1386735033
$1,888.03
in general payments reported to CMS, 2019-2025
12 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $58.12 · 2021: $293 · 2022: $190 · 2023: $393 · 2024: $504 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $712.22 | 2020-2024 | Xifaxan, Trulance |
| Abbvie INC. | $551.59 | 2019-2025 | |
| Janssen Biotech, INC. | $219.57 | 2019-2024 | Stelara |
| Celgene Corporation | $179.65 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $66.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $42.24 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $36.93 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $21.23 | 2024 | |
| Celltrion USA INC. | $16.46 | 2024 | Vegzelma |
| Boston Scientific Corporation | $16.07 | 2023 | |
| Qol Medical, LLC | $14.28 | 2025 | Sucraid |
| Evoke Pharma, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.